title: 5-Fluorouracil, epirubicin and cisplatin in the treatment of metastatic gastric carcinoma: a retrospective analysis of 68 patients.
abstract: BACKGROUND
  Gastric cancer is one of the most common types of cancer and one of the most frequent causes of cancer-related death. The majority of gastric cancers show distant metastasis at the time of diagnosis. At present, there is no general agreement over one standard chemotherapy regimen for metastatic gastric cancer.
  
  
  OBJECTIVE
  We evaluated the activity and toxicity of the combination of 5-Fluorouracil (5-FU), epirubicin and cisplatin (FEP) in previously untreated patients with metastatic gastric cancer.
  
  
  METHODS
  Medical Oncology Department of Uludag University Faculty of Medicine, Bursa; retrospective study.
  
  
  METHODS
  Sixty-eight patients received 5-FU 300 mg/m2 on Days 1-5, epirubicin 50 mg/m2 on Day 1 and cisplatin 60 mg/m2 on Day 1, every 4 weeks. A median of 3.5 cycles was administered. The response rate, time to disease progression, survival and toxic effects were analyzed.
  
  
  METHODS
  Overall survival and time to progression were estimated using Kaplan-Meier method.
  
  
  RESULTS
  There were 4 partial responses and 1 complete response (overall response rate 7.3%); 16 patients had stable disease. Median progression-free and overall survival rates were 3.1 months (95% CI 1.9-4) and 6 months (95% CI 4.2-7), respectively. The principal toxicity was myelosupression. Grade 3-4 neutropenia occurred in 27.9%, anemia in 17.6%, and thrombocytopenia in 11.7% of patients. Non-hematological toxicity was mild and manageable.
  
  
  CONCLUSIONS
  We concluded that FEP combination as used at the doses and schedules in this study has inferior activity against metastatic gastric cancer.
authors.affiliation: Uludag University Faculty of Medicine Department of Medical Oncology, Bursa, Turkey. ozkanat@uludag.edu.tr
authors.forename: Kanat
authors.initials: K
authors.lastname: Ozkan
authors.forename: Evrensel
authors.initials: E
authors.lastname: Turkkan
authors.forename: Kurt
authors.initials: K
authors.lastname: Ender
authors.forename: Demiray
authors.initials: D
authors.lastname: Mutlu
authors.forename: Arslan
authors.initials: A
authors.lastname: Murat
authors.forename: Babacan
authors.initials: B
authors.lastname: Nalan
authors.forename: Yildiz
authors.initials: Y
authors.lastname: Abdulmecit
authors.forename: Manavoglu
authors.initials: M
authors.lastname: Osman
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D002945:Cisplatin / Q000008:administration & dosage; D018572:Disease-Free Survival; D004334:Drug Administration Schedule; D015251:Epirubicin / Q000008:administration & dosage; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D007194:India / Q000453:epidemiology; D008113:Liver Neoplasms / Q000188:drug therapy / Q000556:secondary; D008175:Lung Neoplasms / Q000188:drug therapy / Q000556:secondary; D008207:Lymphatic Metastasis; D008297:Male; D008499:Medical Records; D008875:Middle Aged; D009362:Neoplasm Metastasis; D010051:Ovarian Neoplasms / Q000188:drug therapy / Q000556:secondary; D010534:Peritoneal Neoplasms / Q000188:drug therapy / Q000556:secondary; D012189:Retrospective Studies; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000473:pathology; D016019:Survival Analysis
chemical_list: D015251:Epirubicin; D002945:Cisplatin; D005472:Fluorouracil